473A Stock Overview A clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Adaptimmune Therapeutics plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Adaptimmune Therapeutics Historical stock prices Current Share Price US$0.55 52 Week High US$1.58 52 Week Low US$0.49 Beta 2.18 1 Month Change -8.40% 3 Month Change -31.01% 1 Year Change -8.40% 3 Year Change -83.07% 5 Year Change -57.09% Change since IPO -96.19%
Recent News & Updates
Third quarter 2024 earnings released: US$0.069 loss per share (vs US$0.20 loss in 3Q 2023) Nov 15
Adaptimmune Therapeutics Receives Notice from the Nasdaq Regarding Not in Compliance with Listing Rule 5450(a)(1) Nov 02
Adaptimmune Therapeutics plc to Report Q3, 2024 Results on Nov 13, 2024 Nov 01
New major risk - Revenue and earnings growth Aug 13
Second quarter 2024 earnings released: EPS: US$0.27 (vs US$0.12 loss in 2Q 2023) Aug 13
Adaptimmune Therapeutics plc to Report Q2, 2024 Results on Aug 12, 2024 Aug 05 See more updates
Third quarter 2024 earnings released: US$0.069 loss per share (vs US$0.20 loss in 3Q 2023) Nov 15
Adaptimmune Therapeutics Receives Notice from the Nasdaq Regarding Not in Compliance with Listing Rule 5450(a)(1) Nov 02
Adaptimmune Therapeutics plc to Report Q3, 2024 Results on Nov 13, 2024 Nov 01
New major risk - Revenue and earnings growth Aug 13
Second quarter 2024 earnings released: EPS: US$0.27 (vs US$0.12 loss in 2Q 2023) Aug 13
Adaptimmune Therapeutics plc to Report Q2, 2024 Results on Aug 12, 2024 Aug 05
Adaptimmune Therapeutics plc Receives U.S. FDA Accelerated Approval of TECELRA® Aug 02
New major risk - Revenue and earnings growth May 19
First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.006 profit in 1Q 2023) May 17
New major risk - Financial position May 16
Adaptimmune Therapeutics plc to Report Q1, 2024 Results on May 15, 2024 May 03
Adaptimmune Therapeutics plc, Annual General Meeting, May 14, 2024 Apr 12
New major risk - Shareholder dilution Apr 05
Full year 2023 earnings released: US$0.57 loss per share (vs US$1.03 loss in FY 2022) Mar 08
Adaptimmune Therapeutics plc Appoints Cintia Piccina as Chief Commercial Officer, Effective March 18, 2024 Mar 01
Adaptimmune Therapeutics plc to Report Q4, 2023 Results on Mar 06, 2024 Feb 22
Adaptimmune Therapeutics Regains Nasdaq Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5450(a)(1) Feb 17
Adaptimmune Therapeutics plc Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review Feb 01
Adaptimmune Therapeutics plc Completes Submission of Rolling Biologics License Application to U.S. FDA for Afami-Cel for the Treatment of Advanced Synovial Sarcoma Dec 07
New minor risk - Market cap size Nov 22
Third quarter 2023 earnings released: US$0.20 loss per share (vs US$0.25 loss in 3Q 2022) Nov 09
Adaptimmune Therapeutics plc to Report Q3, 2023 Results on Nov 08, 2023 Oct 26 Adaptimmune Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement of its American Depositary Shares Sep 01
New minor risk - Shareholder dilution Aug 13
Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.28 loss in 2Q 2022) Aug 10
Adaptimmune Therapeutics plc to Report Q2, 2023 Results on Aug 09, 2023 Aug 04
Adaptimmune Therapeutics plc (NasdaqGS:ADAP) completed the acquisition of TCR2 Therapeutics Inc. (NasdaqGS:TCRR) from a group of shareholders. Jun 03
First quarter 2023 earnings released: EPS: US$0.006 (vs US$0.32 loss in 1Q 2022) May 14
Full year 2022 earnings released: US$1.03 loss per share (vs US$1.02 loss in FY 2021) Mar 08
Adaptimmune Therapeutics plc Announces Management Changes Feb 17
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$0.25 loss per share (vs US$0.27 loss in 3Q 2021) Nov 09
Adaptimmune Therapeutics plc to Report Q3, 2022 Results on Nov 08, 2022 Oct 28
Second quarter 2022 earnings released: US$0.28 loss per share (vs US$0.25 loss in 2Q 2021) Aug 05
Adaptimmune Therapeutics plc to Report Q2, 2022 Results on Aug 04, 2022 Jul 22
Insufficient new directors Jun 01
Adaptimmune Therapeutics plc Present Preclinical Proof-Of-Concept Data from Its Second Next-Generation SPEAR T-cell May 17
Adaptimmune Therapeutics plc Appoints Joanna Brewer as Chief Scientific Officer May 05 Adaptimmune Therapeutics plc, Annual General Meeting, May 25, 2022 Apr 13
Adaptimmune Therapeutics plc Presents MAGE-A4 Expression Data from Its Screening Protocol At American Association for Cancer Research Apr 09 Adaptimmune Therapeutics plc announced delayed annual 10-K filing Mar 03
Key Executive recently sold €54k worth of stock Jan 16
Third quarter 2021 earnings released: US$0.27 loss per share (vs US$0.23 loss in 3Q 2020) Nov 06
Adaptimmune Therapeutics plc Announces Clinical Responses Across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation Surpass Trial Sep 14
Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.22 loss in 2Q 2020) Aug 11
Adaptimmune Therapeutics plc Reports Preclinical Data From its HiT Targeting Mesothelin, Being Co-Developed With Astellas, During a Poster Presentation at the American Society for Cell and Gene Therapy (ASGCT) Meeting May 12
First quarter 2021 earnings released: US$0.24 loss per share (vs US$0.23 loss in 1Q 2020) May 06
Adaptimmune Therapeutics plc to Present First Preclinical Data from its HLA-independent TCR Platform at ASGCT Apr 28
Full year 2020 earnings released: US$0.91 loss per share (vs US$1.31 loss in FY 2019) Feb 26
Revenue beats expectations Feb 26
Adaptimmune Therapeutics plc to Report Q4, 2020 Results on Feb 25, 2021 Feb 12
New 90-day high: €5.10 Feb 06
Adaptimmune Therapeutics plc Promotes Elliot Norry, Chief Medical Officer, to Executive Team Effective from January 1, 2021 Dec 18
New 90-day low: €3.50 Dec 10
New 90-day low: €3.68 Nov 24
Third quarter 2020 earnings released: US$0.23 loss per share Nov 11
Revenue beats expectations Nov 11
Adaptimmune Therapeutics plc Presents Initial Tumor Reductions from Early Dose Cohorts of Surpass Trial, At SITC Nov 10
Third quarter 2020 earnings released: US$0.34 loss per share Nov 07
Revenue beats expectations Nov 07
New 90-day low: €5.15 Oct 19
New 90-day high: €8.90 Sep 18
Adaptimmune Therapeutics plc to Report Q2, 2020 Results on Aug 06, 2020 Jul 23 Shareholder Returns 473A DE Biotechs DE Market 7D 1.9% -0.8% -1.6% 1Y -8.4% -13.0% 6.8%
See full shareholder returns
Return vs Market: 473A underperformed the German Market which returned 6.8% over the past year.
Price Volatility Is 473A's price volatile compared to industry and market? 473A volatility 473A Average Weekly Movement 14.5% Biotechs Industry Average Movement 6.9% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 473A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 473A's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center.
Show more Adaptimmune Therapeutics plc Fundamentals Summary How do Adaptimmune Therapeutics's earnings and revenue compare to its market cap? 473A fundamental statistics Market cap €142.46m Earnings (TTM ) -€42.82m Revenue (TTM ) €168.37m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 473A income statement (TTM ) Revenue US$175.04m Cost of Revenue US$143.17m Gross Profit US$31.87m Other Expenses US$76.39m Earnings -US$44.52m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.17 Gross Margin 18.21% Net Profit Margin -25.43% Debt/Equity Ratio 62.3%
How did 473A perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/25 18:15 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Adaptimmune Therapeutics plc is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Peter Lawson Barclays Ying Huang BofA Global Research Olga Smolentseva Bryan Garnier & Co
Show 14 more analysts 
